675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
نویسندگان
چکیده
(ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program Sailaja Puttagunta, MD; Mark Wilcox, MD; Helen Boucher, MD, FIDSA; George Talbot, MD; Michael Dunne, MD; Durata Therapeutics, Branford, CT; Microbiology, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom; Tufts New England Medical Center, Boston, MA; Talbot Advisors LLC, Anna Maria, FL
منابع مشابه
A Prospective Study to Assess Vancomycin Serum Concentrations in Pediatric Patients with Current Dosing Guidelines
Concerns about increasing bacterial resistance to vancomycin, have caused the adult treatment guidelines to recommend higher trough concentrations based on the type and location of infectious disease. Although these recommendations are not specific to children, the values can be extrapolated. This prospective study was designed to evaluate efficacy of current vancomycin dosing recommendations t...
متن کامل266Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
266. Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies Sailaja Puttagunta, MD; Helen Boucher, MD, FIDSA; George Talbot, MD; Mark Wilcox, MD; Michael Dunne, MD; Durata Therapeutics, Branford, CT; Tufts New England Medical Center, Boston, MA; Talbot Advisors LLC, Anna Maria, FL; Microbiology, Leeds T...
متن کاملA Prospective Study to Assess Vancomycin Serum Concentrations in Pediatric Patients with Current Dosing Guidelines
Concerns about increasing bacterial resistance to vancomycin, have caused the adult treatment guidelines to recommend higher trough concentrations based on the type and location of infectious disease. Although these recommendations are not specific to children, the values can be extrapolated. This prospective study was designed to evaluate efficacy of current vancomycin dosing recommendations t...
متن کاملDalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections
Dalbavancin is a lipoglycopeptide antibiotic recently approved by the United States Food and Drug Administration (FDA) for acute bacterial skin and skin structure infections (ABSSSIs). It is active against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and minimum inhibitory concentrations (MICs) are consistently <0.125 µg/ml, much lower than most other a...
متن کامل1331The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
1331. The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Ralph Corey, MD; Matthew Wikler, MD; Greg Moeck,; Hai Jiang,; Samantha Good,; Solo I and II Investigators; Medicine Infectious Diseases, Duke University Medical Center, Durham, NC; The Medicines Company, Parsippany, NJ
متن کامل